Atai Life Sciences CEO discusses Phase 2b trial results for BPL-003 and outlines next steps for treatment-resistant depression.

atai Life Sciences CEO Dr. Srinivas Rao discussed the company's Phase 2b trial results for BPL-003, a short-acting psychedelic for treatment-resistant depression. The study showed strong efficacy and durability, comparable to psilocybin but with a shorter duration of effect. Rao also previewed next steps, including data from an open-label extension and a two-dose induction strategy, and confirmed plans to meet with regulators for end-of-Phase 2 guidance.